We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable
Read MoreHide Full Article
Myriad Genetics, Inc. (MYGN - Free Report) recently announced favorable outcome of its second validation study of the Prolaris test. The latest finding validated this test’s prognostic power to help accurately predict which patients with more aggressive prostate cancer will benefit from intensification of therapy and who may safely avoid such treatments. Notably, this second study was validated by Jonathan Tward M.D of the Department of Radiation Oncology at the University of Utah.
Per management, Myriad Genetics was the first company to present a test that directly measures the molecular biology of an individual patient’s prostate cancer.
The study’s results show major progress in the company’s Oncology business.
Prolaris Test at a Glance
Prolaris is a genetic test designed by Myriad Genetics, equipped to directly measure tumor cell growth. The test, combined with both prostate-specific antigen and Gleason, can assess the degree of aggressiveness of a patient’s individual prostate cancer.
With the updated guidelines in March 2020 at the National Comprehensive Cancer Network, Prolaris was recognized as one of only two prognostic tests to be considered for high-risk patients with prostate cancer.
Notably, approximately 60% of men with prostate cancer currently have insurance or Medicare access to Prolaris.
More on the Study
Management noted that “the new data comes from a second study following previous data, recently published in Clinical Genitourinary Cancer in January 2021, that incorporated men treated surgically or with radiation therapy”.
The new study favors that Prolaris test can more accurately predict the aggressiveness of the cancer, widening the scope for more precise treatment and avoidance of more intense therapies with a patient’s parallel mortality.
Per personnel associated with the study, the new data for Prolaris test helps differentiate the most appropriate personalized treatment path for each patient based on individual tumor behavior. This help healthcare professionals to be able to avoid overtreating patients with therapies including hormone treatment that can significantly impact a patient’s quality of life, while still appropriately treating their prostate cancer.
Industry Prospects
Per a report by Allied Market Research, the global prostate cancer treatment market size was valued at $6,887 million in 2018, and is anticipated to reach $9,904 million by 2026, registering a CAGR of 4.6% Rise in geriatric population, increase in prevalence of prostate cancer and the availability of new prostate cancer treatments are major factors driving the market.
Notable Developments
In January 2021, Myriad Genetics entered into a strategic partnership with Illumina, Inc. (ILMN - Free Report) for enhanced outcomes in Oncology. Per the terms of the time-limited agreement, Illumina will create a kit-based version of Myriad Genetics’ myChoice companion diagnostic (CDx) test for the international market.
In December 2020, Myriad Genetics presented a new study that validates myRisk Hereditary Cancer and riskScore tests. The Study shows that myRisk Hereditary Cancer and riskScore tests can better inform individualized clinical screening and prevention strategies for women at risk of developing breast cancer.
Price Performance
Shares of the company have surged 57% in a year’s time compared with the industry’s growth of 14.9%.
Zacks Rank and Key Picks
Currently, Myriad Genetics carries a Zacks Rank #3 (Hold).
Acorda Therapeutics has a projected long-term earnings growth rate of 14%.
Atea Pharmaceuticals has an estimated long-term earnings growth rate of 164%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable
Myriad Genetics, Inc. (MYGN - Free Report) recently announced favorable outcome of its second validation study of the Prolaris test. The latest finding validated this test’s prognostic power to help accurately predict which patients with more aggressive prostate cancer will benefit from intensification of therapy and who may safely avoid such treatments. Notably, this second study was validated by Jonathan Tward M.D of the Department of Radiation Oncology at the University of Utah.
Per management, Myriad Genetics was the first company to present a test that directly measures the molecular biology of an individual patient’s prostate cancer.
The study’s results show major progress in the company’s Oncology business.
Prolaris Test at a Glance
Prolaris is a genetic test designed by Myriad Genetics, equipped to directly measure tumor cell growth. The test, combined with both prostate-specific antigen and Gleason, can assess the degree of aggressiveness of a patient’s individual prostate cancer.
With the updated guidelines in March 2020 at the National Comprehensive Cancer Network, Prolaris was recognized as one of only two prognostic tests to be considered for high-risk patients with prostate cancer.
Notably, approximately 60% of men with prostate cancer currently have insurance or Medicare access to Prolaris.
More on the Study
Management noted that “the new data comes from a second study following previous data, recently published in Clinical Genitourinary Cancer in January 2021, that incorporated men treated surgically or with radiation therapy”.
The new study favors that Prolaris test can more accurately predict the aggressiveness of the cancer, widening the scope for more precise treatment and avoidance of more intense therapies with a patient’s parallel mortality.
Per personnel associated with the study, the new data for Prolaris test helps differentiate the most appropriate personalized treatment path for each patient based on individual tumor behavior. This help healthcare professionals to be able to avoid overtreating patients with therapies including hormone treatment that can significantly impact a patient’s quality of life, while still appropriately treating their prostate cancer.
Industry Prospects
Per a report by Allied Market Research, the global prostate cancer treatment market size was valued at $6,887 million in 2018, and is anticipated to reach $9,904 million by 2026, registering a CAGR of 4.6% Rise in geriatric population, increase in prevalence of prostate cancer and the availability of new prostate cancer treatments are major factors driving the market.
Notable Developments
In January 2021, Myriad Genetics entered into a strategic partnership with Illumina, Inc. (ILMN - Free Report) for enhanced outcomes in Oncology. Per the terms of the time-limited agreement, Illumina will create a kit-based version of Myriad Genetics’ myChoice companion diagnostic (CDx) test for the international market.
In December 2020, Myriad Genetics presented a new study that validates myRisk Hereditary Cancer and riskScore tests. The Study shows that myRisk Hereditary Cancer and riskScore tests can better inform individualized clinical screening and prevention strategies for women at risk of developing breast cancer.
Price Performance
Shares of the company have surged 57% in a year’s time compared with the industry’s growth of 14.9%.
Zacks Rank and Key Picks
Currently, Myriad Genetics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Acorda Therapeutics, Inc. and Atea Pharmaceuticals, Inc. (AVIR - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank (Strong Buy) stocks here.
Acorda Therapeutics has a projected long-term earnings growth rate of 14%.
Atea Pharmaceuticals has an estimated long-term earnings growth rate of 164%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>